RHJA
PLRX icon

Rice Hall James & Associates’s Pliant Therapeutics PLRX Stock Holding History

Rice Hall James & Associates’s Portfolio PLRX Stock Details PLRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-147,705
Closed -$180K – 253
2025
Q4 		$180K Buy
147,705
+2,862
+2% +$4.3K 0.01% 243
2025
Q3 		$214K Sell
144,843
-16,405
-10% -$25K 0.01% 246
2025
Q2 		$187K Buy
161,248
+8,254
+5% +$11.7K 0.01% 247
2025
Q1 		$207K Sell
152,994
-7,528
-5% -$45.7K 0.01% 248
2024
Q4 		$2.11M Buy
160,522
+3,305
+2% +$45.1K 0.12% 171
2024
Q3 		$1.76M Buy
157,217
+29,583
+23% +$370K 0.1% 184
2024
Q2 		$1.37M Buy
+127,634
New +$1.65M 0.08% 192

Other funds holding PLRX

TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
MAM
Monaco Asset Management Monaco $1.26B AUM 60.23% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return

Rice Hall James & Associates's PLRX Position: Q1 2026 in Review

Rice Hall James & Associates sold out of Pliant Therapeutics (PLRX) in Q1 2026, closing a stake of 147,705 shares — an estimated $180K sold.

Rice Hall James & Associates first reported a position in PLRX in Q2 2024 and held it in 7 quarters. The position peaked at $2.11M in Q4 2024. 91 funds tracked by Wall St. Rank hold PLRX as of Q1 2026.

  • Rice Hall James & Associates reported no remaining Pliant Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Rice Hall James & Associates sold 147,705 Pliant Therapeutics shares in Q1 2026, an estimated $180K.
  • Rice Hall James & Associates first reported a position in Pliant Therapeutics in Q2 2024 and held it in 7 quarters.
  • Rice Hall James & Associates's Pliant Therapeutics position peaked at $2.11M in Q4 2024.
  • 91 funds tracked by Wall St. Rank held Pliant Therapeutics as of Q1 2026.

Based on Rice Hall James & Associates's 13F filing for Q1 2026, filed 15 May 2026.